{"id":"placebo-to-zostavax","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Injection site swelling"},{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL6068498","moleculeType":"Vaccine component"},"_fixedAt":"2026-03-30T12:48:43.813552","_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebo serves as the inactive control comparator in Phase 3 trials of ZOSTAVAX. ZOSTAVAX itself is a live attenuated vaccine that stimulates cell-mediated and humoral immune responses against varicella-zoster virus to reduce the incidence and severity of herpes zoster and post-herpetic neuralgia in immunocompetent adults aged 50 years and older.","oneSentence":"This is a placebo control arm in a clinical trial comparing against ZOSTAVAX, a live attenuated varicella-zoster virus vaccine designed to prevent herpes zoster (shingles) in older adults.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:59.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of herpes zoster (shingles) in adults aged 50 years and older"}]},"_fixedFields":["pubmed(15)"],"trialDetails":[{"nctId":"NCT02519855","phase":"PHASE3","title":"Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-11","conditions":"Herpes Zoster","enrollment":882},{"nctId":"NCT02958345","phase":"PHASE4","title":"Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™","status":"COMPLETED","sponsor":"Tulane University","startDate":"2013-06","conditions":"Herpes Zoster, Fibrosis","enrollment":28},{"nctId":"NCT00550745","phase":"PHASE4","title":"ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09","conditions":"Herpes Zoster","enrollment":11999},{"nctId":"NCT00546819","phase":"PHASE2","title":"ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Herpes Zoster","enrollment":309},{"nctId":"NCT00535730","phase":"PHASE3","title":"ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Herpes Zoster, Pneumococcal Infection","enrollment":473},{"nctId":"NCT00534248","phase":"PHASE3","title":"Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Shingles","enrollment":22439},{"nctId":"NCT01385566","phase":"PHASE1","title":"A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09","conditions":"Herpes Zoster","enrollment":223},{"nctId":"NCT00886613","phase":"PHASE1","title":"A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03","conditions":"Herpes Zoster","enrollment":120},{"nctId":"NCT00231816","phase":"PHASE3","title":"A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Herpes Zoster","enrollment":763},{"nctId":"NCT00322231","phase":"PHASE3","title":"A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Herpes Zoster","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to ZOSTAVAX™","genericName":"Placebo to ZOSTAVAX™","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"This is a placebo control arm in a clinical trial comparing against ZOSTAVAX, a live attenuated varicella-zoster virus vaccine designed to prevent herpes zoster (shingles) in older adults. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}